# ICS Medical Advisory (ICSMA-20-233-01)
## Philips SureSigns VS4
Original release date: August 20, 2020
[Print Document](javascript:window.print\(\);)
[Tweet](https://twitter.com/share?url=https%3A%2F%2Fus-
cert.cisa.gov%2Fics%2Fadvisories%2Ficsma-20-233-01)
[Like Me](https://www.facebook.com/sharer.php?u=https%3A%2F%2Fus-
cert.cisa.gov%2Fics%2Fadvisories%2Ficsma-20-233-01)
[Share](http://www.addthis.com/bookmark.php?url=https%3A%2F%2Fus-
cert.cisa.gov%2Fics%2Fadvisories%2Ficsma-20-233-01)
### Legal Notice
All information products included in [https://us-cert.gov/ics](/ics) are
provided "as is" for informational purposes only. The Department of Homeland
Security (DHS) does not provide any warranties of any kind regarding any
information contained within. DHS does not endorse any commercial product or
service, referenced in this product or otherwise. Further dissemination of
this product is governed by the Traffic Light Protocol (TLP) marking in the
header. For more information about TLP, see [https://www.us-
cert.gov/tlp/](/tlp/).
* * *
## 1\. EXECUTIVE SUMMARY
* **CVSS v3 6.3**
* **ATTENTION** : Exploitable remotely
* **Vendor** : Philips
* **Equipment** : SureSigns VS4
* **Vulnerabilities** : Improper Input Validation, Improper Access Control, Improper Authentication
## 2\. RISK EVALUATION
Successful exploitation of these vulnerabilities could allow an attacker
access to administrative controls and system configurations, which could allow
changes to system configuration items causing patient data to be sent to a
remote destination.
## 3\. TECHNICAL DETAILS
### 3.1 AFFECTED PRODUCTS
The following versions of SureSigns VS4, a vital signs patient monitor, are
affected:
* SureSigns VS4 A.07.107 and prior
### 3.2 VULNERABILITY OVERVIEW
**3.2.1 [IMPROPER INPUT VALIDATION
CWE-20](https://cwe.mitre.org/data/definitions/20.html)**
The product receives input or data, but it does not validate or incorrectly
validates that the input has the properties required to process the data
safely and correctly.
[CVE-2020-16237](http://web.nvd.nist.gov/view/vuln/detail?vulnId=CVE-2020-16237)
has been assigned to this vulnerability. A CVSS v3 base score of 2.1 has been
calculated; the CVSS vector string is
([AV:P/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:L](https://www.first.org/cvss/calculator/3.0#CVSS:3.0/AV:P/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:L)).
**3.2.2 [IMPROPER ACCESS CONTROL
CWE-284](https://cwe.mitre.org/data/definitions/284.html)**
The software does not restrict or incorrectly restricts access to a resource
from an unauthorized actor.
[CVE-2020-16241](http://web.nvd.nist.gov/view/vuln/detail?vulnId=CVE-2020-16241)
has been assigned to this vulnerability. A CVSS v3 base score of 6.3 has been
calculated; the CVSS vector string is
([AV:P/AC:H/PR:N/UI:N/S:C/C:L/I:L/A:H](https://www.first.org/cvss/calculator/3.0#CVSS:3.0/AV:P/AC:H/PR:N/UI:N/S:C/C:L/I:L/A:H)).
**3.2.3 [IMPROPER AUTHENTICATION
CWE-287](https://cwe.mitre.org/data/definitions/287.html)**
When an actor claims to have a given identity, the software does not prove or
insufficiently proves the claim is correct.
[CVE-2020-16239](http://web.nvd.nist.gov/view/vuln/detail?vulnId=CVE-2020-16239)
has been assigned to this vulnerability. A CVSS v3 base score of 4.9 has been
calculated; the CVSS vector string is
([AV:N/AC:L/PR:H/UI:N/S:U/C:H/I:N/A:N](https://www.first.org/cvss/calculator/3.0#CVSS:3.0/AV:N/AC:L/PR:H/UI:N/S:U/C:H/I:N/A:N)).
### 3.3 BACKGROUND
* **CRITICAL INFRASTRUCTURE SECTORS** : Healthcare and Public Health
* **COUNTRIES/AREAS DEPLOYED** : Worldwide
* **COMPANY HEADQUARTERS LOCATION** : Netherlands
### 3.4 RESEARCHER
Cleveland Clinic reported these vulnerabilities to Philips.
## 4\. MITIGATIONS
As a mitigation to these vulnerabilities, Philips recommends users change all
system passwords on the SureSigns VS4 with unique passwords for each device
and secure the device when not in use to prevent unauthorized access, as
referenced in the Installation and Configuration Guide available on Incenter.
Philips also recommends users consider replacing the SureSigns VS4 device with
a newer technology.
Users with questions regarding specific SureSigns VS4 patient monitor
installations and upgrade options should contact [Philips service support or
regional service
support](https://www.usa.philips.com/healthcare/solutions/customer-service-
solutions) or call 1-800-722-9377.
Please see the [Philips advisory](http://www.philips.com/productsecurity) for
vulnerabilities discussed in this disclosure, and visit the [Philips product
security website](https://www.philips.com/productsecurity) for the latest
security information for Philips products.
CISA recommends users take defensive measures to minimize the risk of
exploitation of these vulnerabilities. Specifically, users should:
* Implement physical security measures to limit or control access to critical systems.
* Restrict system access to authorized personnel only and follow a least privilege approach.
* Apply defense-in-depth strategies.
* Disable unnecessary accounts and services.
* Where additional information is needed, refer to existing [cybersecurity in medical device guidance issued by the FDA](https://www.fda.gov/MedicalDevices/DigitalHealth/ucm373213.htm).
CISA reminds organizations to perform proper impact analysis and risk
assessment prior to deploying defensive measures.
CISA also provides a section for [control systems security recommended
practices](https://www.us-cert.gov/ics/recommended-practices) on the ICS
webpage on [us-cert.gov](https://www.us-cert.gov/ics). Several recommended
practices are available for reading and download, including [Improving
Industrial Control Systems Cybersecurity with Defense-in-Depth
Strategies](https://www.us-
cert.gov/sites/default/files/recommended_practices/NCCIC_ICS-
CERT_Defense_in_Depth_2016_S508C.pdf).
Additional mitigation guidance and recommended practices are publicly
available on the [ICS webpage on us-cert.gov](https://www.us-cert.gov/ics) in
the Technical Information Paper, [ICS-TIP-12-146-01B--Targeted Cyber Intrusion
Detection and Mitigation Strategies](https://www.us-cert.gov/ics/tips/ICS-
TIP-12-146-01B).
Organizations observing any suspected malicious activity should follow their
established internal procedures and report their findings to CISA for tracking
and correlation against other incidents.
No known public exploits specifically target these vulnerabilities. Low skill
level is needed to exploit.
暂无评论